Outlook Therapeutics (BST:41ON) - Aandelenkoers, Nieuws & Analyse

41ON Overzicht aandelen

Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Meer informatie

41ON fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 61.33% per jaar groeien

Risicoanalyse

Negatief eigen vermogen

Aandelen zijn zeer illiquide

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Outlook Therapeutics, Inc. Concurrenten

Heidelberg Pharma

XTRA:HPHA

€105.8m

2invest

XTRA:2INV

€62.7m

4SC

DB:VSC

€50.2m

Formycon

XTRA:FYB

€857.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Outlook Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$7.28
52 Week Hoogtepunt	US$31.60
52 Week Laag	US$3.80
Bèta	0.19
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-78.23%
5 jaar verandering	-68.66%
Verandering sinds IPO	-94.56%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	41ON	DE Biotechs	DE Markt
7D	0%	-1.1%	1.1%
1Y	n/a	-18.8%	7.2%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe 41ON presteerde ten opzichte van de German Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe 41ON presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is 41ON's price volatile compared to industry and market?
41ON volatility
41ON Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: 41ON heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 41ON in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	24	Russ Trenary	www.outlooktherapeutics.com

Outlook Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Outlook Therapeutics zich tot de beurswaarde?
41ON fundamentele statistieken
Marktkapitalisatie	€171.05m
Inkomsten(TTM)	-€48.35m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-3.5x

Koers/Winstverhouding

Is 41ON overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
41ON resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$21.12m
Brutowinst	-US$21.12m
Overige uitgaven	US$30.38m
Inkomsten	-US$51.50m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.31
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	-150.1%

Hoe presteerde 41ON op de lange termijn?

Bekijk historische prestaties en vergelijking

41ON Overzicht aandelen

Beloningen

Risicoanalyse

Outlook Therapeutics, Inc. Concurrenten

XTRA:HPHA

€105.8m

XTRA:2INV

€62.7m

DB:VSC

€50.2m

XTRA:FYB

€857.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Recent updates

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

New major risk - Negative shareholders equity

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Outlook Therapeutics, Inc. Announces Executive Appointments

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought €227k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc. to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Forecast to breakeven in 2023

Outlook Therapeutics, Inc. Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial

Forecast breakeven pushed back to 2024

Outlook Therapeutics, Inc. Provides Update on the Clinical Progress of ONS-5010 (Bevacizumab-Vikg) in Virtual Clinical Day

Outlook Therapeutics, Inc., Annual General Meeting, Mar 24, 2021

Chief Operating Officer recently sold €134k worth of stock

Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™

Outlook Therapeutics, Inc. Recent Financing Secures Funding to Support Ons-5010 / Lytenava™ Through Planne Bla Submission

New 90-day high: €1.39

New 90-day high: €1.07

Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

New 90-day high: €1.04

Outlook Therapeutics, Inc. Announces Board Appointments

Outlook Therapeutics, Inc. announced that it has received $10 million in funding